Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus standard chemotherapy in Chinese patients with MSI-H/dMMR stage IV colorectal cancer
CTR20220264Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Jun 2022; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220264.